1. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
- Author
-
Bente Glintborg, Merete Lund Hetland, Tore K Kvien, Brigitte Michelsen, Florenzo Iannone, Karel Pavelka, Ziga Rotar, Maria Jose Santos, Catalin Codreanu, Anne Gitte Loft, Maria Sole Chimenti, Gary J Macfarlane, Gareth T Jones, Mikkel Østergaard, Jakub Zavada, Bjorn Gudbjornsson, Gerður Gröndal, Lykke Midtbøll Ørnbjerg, Adrian Ciurea, Daniela Di Giuseppe, Michael J Nissen, Anabela Barcelos, Irene van der Horst-Bruinsma, Sara Nysom Christiansen, Isabel Castrejón, Sella Aarrestad Provan, Heikki Relas, Simon Horskjær Rasmussen, Ismail Sari, Anna-Mari Hokkanen, Johan K Wallman, Sigrid Vorobjov, Marion Pons, Marleen van de Sande, Corina Mogosan, Lucia Otero-Varela, Karin Laas, Yesim Erez, and Katja Perdan Pirkmajer
- Subjects
Medicine - Abstract
Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID)
- Published
- 2024
- Full Text
- View/download PDF